Medical lab technologists
Official title Medical and Clinical Laboratory Technologists (SOC 29-2011)
Also called Medical laboratory scientist, Clinical laboratory scientist, CLS, MLS, MLS(ASCP)
In brief
BLS last counted US medical lab technologists as their own occupation in May 2016: 166,730 jobs. Median pay was $61,070 a year in May 2016. The earliest figure here is an estimate of 35,000 from 1943, not measured the same way as today's count. The last full technology era for medical lab technologists: Molecular diagnostics and MALDI-TOF mass spectrometry, 2000 to 2018.
What the sources say
Official outlook
BLS's 2025-35 employment projections do not list this occupation on its own.
AI exposure studies
- 23.2% of this job's tasks are exposed to large language models. Not a forecast of job losses. Eloundou and others, 2023
Data as of BLS OEWS May 2016.
Last updated .
Cite this page
Future History. (2026, October 11). Medical lab technologists: jobs and pay since 1943 [Data set; data as of BLS OEWS May 2016]. https://futurehistory.earth/timeline/29-2011
Future History. "Medical lab technologists: jobs and pay since 1943." Data as of BLS OEWS May 2016. Last modified October 11, 2026. https://futurehistory.earth/timeline/29-2011.
@misc{futurehistory_29_2011, author = {{Future History}}, title = {Medical lab technologists: jobs and pay since 1943}, year = {2026}, month = oct, howpublished = {\url{https://futurehistory.earth/timeline/29-2011}}, note = {Last updated 2026-10-11. Data as of BLS OEWS May 2016}, }
The access date is today's date on your device.
OEWS stopped publishing this occupation on its own after May 2016. From May 2017 it counts it only within 29-2010 (Clinical Laboratory Technologists and Technicians), together with laboratory technicians, so this series ends in 2016.
≈ $79,818 in 2024 prices (derived by us, CPI-adjusted)
The American College of Surgeons mandates that accredited hospitals must have a functioning clinical laboratory. The standard creates overnight demand for trained laboratory personnel that hospitals cannot fill: pathologists alone cannot perform the rapidly expanding test menu. Pathologists begin training women assistants to perform routine tests, planting the seed of a profession with no title, no credential, and no professional organization of its own.
The American Society of Clinical Pathology establishes the Board of Registry, the first standardized credentialing body for laboratory professionals. The Board creates two classifications: Laboratory Technician (lower tier) and Medical Technologist (upper tier), with minimum educational and experience requirements for each. The credential gives the occupation a name, a standard, and the beginning of a professional identity separate from the pathologists who employed them.
The American Society of Medical Technologists (ASMT) is incorporated, giving the profession an independent advocacy organization separate from the pathologist-controlled ASCP Board of Registry. The formation of ASMT reflected years of resentment at ASCP's requirement that medical technologists work under pathologist supervision at all times. ASMT was renamed the American Society for Clinical Laboratory Science (ASCLS) in 1973 and remains the primary professional organization for medical laboratory scientists.
Leonard T. Skeggs licenses his continuous-flow analysis technology to the Technicon Corporation, which commercializes it as the AutoAnalyzer. The instrument processes up to 40 blood chemistry samples per hour per channel, automating tests that previously required individual manual pipetting for each specimen. Technicon's marketing slogan is "increasing the productivity of the clinical laboratory." The AutoAnalyzer is the first wave of laboratory automation. It does not eliminate the medical technologist; it changes the job from pipette-and-Bunsen-burner craftsmanship to instrument monitoring and result interpretation.
Medicare and Medicaid are enacted (Social Security Amendments of 1965). The coverage of laboratory testing for the elderly and low-income populations creates an explosion in clinical laboratory test orders. Between 1965 and 1980, clinical laboratory test volume in the US grows by an estimated 10-15x. Laboratories expand rapidly, wages begin rising to attract workers to a profession that had been chronically underpaid, and the number of accredited training programs grows from under 300 in the early 1960s to nearly 1,000 by 1970.
The Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) are signed into law on October 31, 1988, after a 1987 Wall Street Journal investigation documented false-negative Pap smear results at cytology laboratories with no federal oversight. CLIA establishes three test-complexity tiers (waived, moderate, high) and imposes mandatory quality control, proficiency testing, and personnel qualification requirements on all US clinical laboratories regardless of setting. For medical laboratory technologists, CLIA '88 means that every result now requires documented verification, every quality control failure requires a written corrective action, and every technologist's competency must be assessed annually for every test system performed. CLIA is the regulatory floor that no automation wave can remove: it mandates human verification of laboratory results as a federal law, not a hospital policy.
ASCLS formally adopts "clinical laboratory science" as the preferred professional title for the field, replacing "medical technology" after decades of debate about names that failed to convey the scientific depth of the work. The title Medical Laboratory Scientist (MLS) and the credential MLS(ASCP)CM gradually replace Medical Technologist (MT) and MT(ASCP), though both credentials remain valid. The renaming reflects a long-standing professional frustration: the word "technologist" was widely interpreted by the public (and, more damagingly, by hospital human resources departments) as interchangeable with "technician," obscuring the bachelor's-degree educational requirement and suppressing wages relative to other bachelor's-level healthcare professions.
The COVID-19 pandemic arrives and US clinical laboratories are immediately overwhelmed. The SARS-CoV-2 PCR test, a molecular diagnostic procedure requiring MLS-level expertise, needs to be performed at a volume the existing laboratory workforce cannot absorb. A peer-reviewed study published in the Journal of Clinical Microbiology documents critical supply and workforce shortages in clinical and public health laboratories by mid-2020. The pandemic makes visible to the broader public what laboratory professionals had been saying for decades: the invisible infrastructure of medicine had been chronically underfunded, understaffed, and unrecognized. After the pandemic, laboratory professional vacancies and wages rose substantially. The ASCP 2021 Wage Survey documented a "critical moment in the post-COVID era" as laboratory directors scrambled to fill open positions.
Will AI replace medical lab technologists? What the research says
Each figure is stated by the named source; we publish no forecasts of our own. Where sources disagree, we show the disagreement rather than an average.
Each figure is stated by the named source; we publish no forecasts of our own. Where sources disagree, the spread is the honest signal.
What's changing day to day for medical lab technologists
Three parts of your work where AI is already doing real lifting, and what stays yours.
AI is sitting alongside you herePerform and QC AI-assisted hematology differential counts, operating the CellaVision DM9600 or Sysmex DI-60 digital morphology system on blood smears reflexed from the CBC analyzer, reviewing AI pre-classified leukocyte categories (neutrophils, lymphocytes, monocytes, eosinophils, basophils, blasts, atypical lymphocytes, band forms), reclassifying AI errors at the cell level, identifying clinically significant abnormal morphology (hypersegmented neutrophils, schistocytes, plasma cells), and releasing the finalized differential to the LIS for physician reporting.
Perform and QC AI-assisted hematology differential counts, operating the CellaVision DM9600 or Sysmex DI-60 digital morphology system on blood smears reflexed from the CBC analyzer, reviewing AI pre-classified leukocyte categories (neutrophils, lymphocytes, monocytes, eosinophils, basophils, blasts, atypical lymphocytes, band forms), reclassifying AI errors at the cell level, identifying clinically significant abnormal morphology (hypersegmented neutrophils, schistocytes, plasma cells), and releasing the finalized differential to the LIS for physician reporting.[4],[5],[1]
CellaVision and Sysmex DI-60 AI have fundamentally changed hematology differential workflows: technologists review AI-pre-classified cell presentations rather than classifying every cell under the microscope. AI is highly accurate on normal morphology, reducing per-slide review time on straightforward cases. Your defensibility is entirely in the exception: AI digital morphology fails most on the cases that matter most clinically, blast vs. reactive lymphocyte differentiation in an acute leukemia workup, schistocyte quantification in thrombotic microangiopathy, hypersegmented neutrophil identification for B12 deficiency, and atypical forms in EBV or CMV. Build deep expertise in abnormal cell morphology: study ASCP morphology flashcards, use CellaVision's Atlas for reference cell review, and practice calling the hardest cases that the AI pre-classifies incorrectly. The technologist who catches the blast flagged as 'atypical lymphocyte' by the AI is clinically irreplaceable; the technologist who only validates the normal cases is not.
AI is sitting alongside you herePerform AI-assisted urinalysis microscopy oversight, loading urine specimens onto the Iris iQ200 or similar automated urine microscopy analyzer, reviewing AI-classified sediment images (RBCs, WBCs, casts, bacteria, crystals, epithelial cells) for accuracy, performing manual wet-prep microscopy on AI-discrepant or clinically flagged cases, correlating microscopy findings with dipstick chemistry results, and releasing the complete urinalysis result to the LIS.
Perform AI-assisted urinalysis microscopy oversight, loading urine specimens onto the Iris iQ200 or similar automated urine microscopy analyzer, reviewing AI-classified sediment images (RBCs, WBCs, casts, bacteria, crystals, epithelial cells) for accuracy, performing manual wet-prep microscopy on AI-discrepant or clinically flagged cases, correlating microscopy findings with dipstick chemistry results, and releasing the complete urinalysis result to the LIS.[6],[9],[1]
Iris iQ200 AI has displaced the routine wet-prep urine microscopy step for the majority of urine specimens at large core labs: technologists review AI-classified sediment images rather than performing manual microscopy on every specimen. AI accuracy is high for common elements (bacteria, WBCs, RBCs) but degrades on: casts vs. mucus differentiation, WBC cast vs. granular cast, RBC dysmorphology for glomerular bleeding vs. lower urinary tract. Develop your manual wet-prep microscopy skill as your differentiator: the technologist who can reliably distinguish waxy cast from broad cast under the microscope, or identify an RBC cast in a patient with new proteinuria, is providing clinical value no iQ200 algorithm delivers. Always correlate microscopy with dipstick chemistry: an iQ200 that shows rare bacteria in a specimen with normal nitrite and WBC on dipstick is a contamination flag, not a UTI result. CLIA and CAP require documentation of manual verification for discrepant automated results.
AI is sitting alongside you hereProcess and operate AI-assisted high-volume CBC and chemistry analyzers, loading specimens onto the Beckman Coulter DxH 900 or equivalent CBC platform, reviewing AI-generated analyzer flags (blast flag, immature granulocyte flag, nucleated RBC flag, atypical lymphocyte flag), determining which flagged specimens require reflexive manual review or digital morphology, running chemistry panels on automated analyzers (comprehensive metabolic panel, lipids, cardiac enzymes), verifying QC results are within control limits before releasing patient results, and troubleshooting out-of-control QC with corrective action documentation.
Process and operate AI-assisted high-volume CBC and chemistry analyzers, loading specimens onto the Beckman Coulter DxH 900 or equivalent CBC platform, reviewing AI-generated analyzer flags (blast flag, immature granulocyte flag, nucleated RBC flag, atypical lymphocyte flag), determining which flagged specimens require reflexive manual review or digital morphology, running chemistry panels on automated analyzers (comprehensive metabolic panel, lipids, cardiac enzymes), verifying QC results are within control limits before releasing patient results, and troubleshooting out-of-control QC with corrective action documentation.[12],[1],[8]
CBC and chemistry analyzers now run largely autonomously in high-volume core labs: AI flagging logic determines which results need reflexive review without technologist first-look for every specimen. Your defensibility is in QC governance and reflex logic design: understanding Westgard rules and multi-rule QC interpretation, recognizing when a QC failure pattern signals an instrument problem vs. a reagent lot issue vs. a systematic calibration drift, and maintaining the reflex testing algorithms that determine when AI flags trigger digital morphology. Technologists who understand the analytical chemistry behind the flags (why does the DxH blast flag fire on certain chronic lymphocytic leukemia specimens? why does the platelet clumping flag appear even with EDTA-anticoagulated specimens?) are the ones who catch systematic errors before they reach the patient report. Build Westgard rule proficiency and deepen your instrument-specific troubleshooting knowledge: this is the QC expertise that supervisors promote.
Where medical lab technologists go next
Natural next steps for someone with your foundation: not exits, evolutions.
- Medical and Health Services Managers
- US median pay
- $123,860 (May 2025)
- BLS outlook 2025-35
- +24.2%
- Health Informatics SpecialistsNo timeline for this role yet
- Medical Scientists, Except Epidemiologists
- US median pay
- $103,410 (May 2025)
- BLS outlook 2025-35
- +12.6%
What each move takes
Medical and Health Services Managers
Senior MLS professionals with charge tech, lead technologist, or laboratory section supervisor experience are positioned for laboratory director, laboratory manager, and clinical laboratory administrator roles tracked under Medical and Health Services Managers. Laboratory management is one of the most natural MLS career escalations: laboratory managers at most U.S. hospitals are required to have clinical laboratory credentials (ASCP MLS or MT) plus management experience; the role does not necessarily require a separate degree. As AI-assisted analyzers (CellaVision, Navify, iQ200) reshape laboratory workflows, health systems need laboratory managers who understand the clinical technology and can govern AI platform deployment, vendor contracts, CAP inspection preparation, and CLIA compliance. MLS professionals who take on charge tech or quality coordinator responsibilities, lead instrument validation studies, and develop budgeting and scheduling skills are directly building toward laboratory management. Formal pathway: ASCP Laboratory Management Certificate or a master's degree in health administration (MHA) for larger system-level roles.
- · Charge tech / lead technologist experience: managing daily bench assignments, QC review, critical value escalation, and shift handoff documentation at the section or laboratory level
- · ASCP Laboratory Management Certificate: covers laboratory operations, budgeting, regulatory compliance (CLIA, CAP, Joint Commission), personnel management, and quality systems; the primary management credential for MLS professionals targeting laboratory director roles
- · Laboratory finance basics: laboratory cost-per-test analysis, reagent contract negotiation, analyzer lease vs. purchase analysis, and CPT code billing for laboratory services; laboratory managers are responsible for section P&L in many health systems
- · AI vendor management in clinical laboratory: evaluating AI analyzer platforms (CellaVision vs. Sysmex DI-60, Navify vs. competing CDS platforms), managing deployment agreements, and monitoring algorithm performance metrics post-go-live
- · CLIA and CAP regulatory management: personnel qualification documentation, QC program oversight, proficiency testing enrollment and deadline management, and CAP inspection preparation, the core regulatory compliance functions a laboratory manager owns
How has the work of medical lab technologists changed since 1919?
The tools that defined the work, one line per era. Select an era to see how it reshaped the work.
Manual bench methods (microscopy, Bunsen burner, Kahn tube test, hand-pipetting)
The first clinical laboratory technologists worked entirely by hand. A blood count meant placing a drop of blood on a hemocytometer slide, counting cells in a defined grid under a bright-field microscope, and calculating the result with pencil and paper. A urine analysis meant pipetting specimen into a centrifuge tube, reading the specific gravity with a urinometer, then reading the sediment under the microscope. Every test was a craft skill. The quality of a result depended almost entirely on the technologist's manual precision, visual acuity, and knowledge of what to look for. There were no electronic instruments, no automated dispensers, and no printed readouts: every result was read by a human eye and transcribed by hand into a paper logbook.
Technicon AutoAnalyzer and continuous-flow chemistry automation
In 1957, Leonard T. Skeggs at the Cleveland Clinic licensed his continuous-flow analysis technology to the Technicon Corporation, which commercialized it as the AutoAnalyzer. The AutoAnalyzer channeled serum specimens through tubing at many samples per hour per channel, performing colorimetric reactions for glucose, BUN, creatinine, cholesterol, and dozens of other chemistry analytes automatically and printing a continuous paper graph of results. The Smithsonian Institution holds an original Technicon AutoAnalyzer as a landmark invention. According to biomolecular systems historians, the AutoAnalyzer allowed a hundredfold increase in the number of laboratory tests performed over the decade following its introduction. This first automation wave did not eliminate medical technologists: it created a new kind of work. Someone had to set up the manifolds, calibrate the colorimeter, recognize when a tube had air bubbles that would corrupt a result, and interpret the chart paper. Manual dexterity and visual judgment were still central, just applied to machine maintenance rather than pipette technique.
Effect on the workThe AutoAnalyzer increased throughput per technologist for chemistry panels, enabling the same number of technologists to handle the explosion in test orders driven by Medicare and Medicaid (enacted 1965). Without automation, the clinical laboratory workforce would have needed to be larger to absorb the Medicare-era testing surge.
Automated hematology analyzers (Coulter Counter, first 3-part and 5-part differential CBC)
Wallace Coulter patented the Coulter principle for counting blood cells electrically in 1953, and the Coulter Counter entered clinical laboratory use in the 1960s. By the mid-1970s, automated CBC analyzers had replaced the manual hemocytometer blood count in most US hospital laboratories. Early instruments produced only a 3-part WBC differential (neutrophils, lymphocytes, "other"); by the early 1980s, 5-part differential analyzers (Technicon H-6000, Coulter S-Plus) could classify all five major WBC types electronically. The manual 100-cell differential under the microscope became a reflex procedure reserved for abnormal flags, representing a fundamental reorganization of the hematology technologist's day. Technologists no longer classified every cell on every specimen; they now managed QC on instruments that classified thousands of specimens per shift and intervened when the analyzer flagged something it could not classify. This is the same human-machine relationship that AI digital morphology tools (CellaVision, Sysmex DI-60) recapitulated at a deeper level four decades later.
Effect on the workA 1980 hematology laboratory technologist handled substantially more specimens per shift than a 1965 technologist, and the skill set shifted from manual cell classification to instrument management and exception interpretation. The manual microscopy skill remained essential for flagged cases; its application narrowed from every specimen to the cases that mattered most.
CLIA '88 and laboratory information systems (LIS)
The Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) were signed into law after a 1987 Wall Street Journal investigation documented false-negative Pap smear results at cytology laboratories. CLIA established three complexity tiers for laboratory tests (waived, moderate, and high complexity) and imposed federally mandated quality control, proficiency testing, and personnel qualification requirements. For medical laboratory technologists, CLIA meant that every test result now required documented verification, every QC failure required written corrective action, and every technologist's competency had to be assessed annually for every test system they performed. Simultaneously, laboratory information systems (LIS) began replacing paper logbooks. Systems like Sunquest (acquired 1997), Cerner PathNet, and Meditech brought computerized result entry, delta-check alerting, and automatic LIS-to-EHR result routing. By the mid-1990s, the technologist's workstation was a computer terminal, not a pencil and paper. The combination of CLIA documentation requirements and LIS capability reshaped the job: the paperwork burden increased substantially, but so did the data visibility and error-detection capability.
Molecular diagnostics and MALDI-TOF mass spectrometry
The polymerase chain reaction (PCR), invented in 1983 and commercialized through the 1990s, became the backbone of clinical molecular diagnostics by the 2000s. Clinical laboratories added molecular sections to identify respiratory viruses, detect MRSA nasal carriage, diagnose C. diff infection, and detect HIV and hepatitis viral loads. In 2013, MALDI-TOF mass spectrometry (Bruker Biotyper, bioMerieux Vitek MS) received FDA clearance for clinical use and began replacing the conventional culture-and-biochemical-characterization workflow for blood culture organism identification: MALDI-TOF delivers genus-species ID in several minutes from a positive blood culture pellet. Both technologies required medical laboratory technologists to acquire skills in molecular biology, nucleic acid extraction, and instrument-specific software interpretation that went well beyond the classical chemistry-and-microscopy curriculum. Technologists who mastered molecular and mass spectrometry workflows found themselves in the highest-paying and fastest-growing laboratory specialty sections.
AI digital morphology, automated urinalysis, and laboratory clinical decision support
CellaVision AB (acquired by Sysmex in 2021) commercialized the first AI-powered digital cell morphology system in clinical laboratory use, and by 2015 the DM9600 was deployed in over 1,200 US laboratories. Using deep-learning neural networks trained on more than 500,000 annotated cell images, the DM9600 pre-classifies peripheral blood smear leukocytes across normal and pathological categories (blasts, atypical lymphocytes, hypersegmented neutrophils, plasma cells) and presents them in a gallery for technologist review. Clinical Laboratory News reported in 2024 that CellaVision AI reduces manual differential time approximately 80% in high-volume hematology laboratories. The Iris iQ200 automated urinalysis system similarly replaced routine wet-prep microscopy with AI-classified sediment images. Roche Navify Algorithm Suite brought AI sepsis risk scoring and coagulation alerts into the LIS workflow. These tools are not eliminating the technologist role; they are concentrating it toward the exception cases that the AI cannot handle: blast differentiation in acute leukemia workups, schistocyte quantification in thrombotic microangiopathy, and pre-call result verification before clinician notification. The technologist who can catch the blast the AI mislabeled as a reactive lymphocyte is providing value no algorithm delivers at scale.
Effect on the workAI digital morphology tools increased hematology throughput per technologist, allowing laboratories to manage rising test volumes without proportional staffing increases. The COVID-19 pandemic (2020-2021) revealed the limits of this efficiency: when testing volume surged to unprecedented levels for SARS-CoV-2 PCR, the clinical laboratory workforce shortage became a national public health constraint.
See the same long-arc view for your own profession.
Browse the directory by industry, or search by title or SOC code.
Browse all rolesMedical and Clinical Laboratory Technologists employment and pay by year
In other countries
The latest figure each country's statistics agency publishes for this job. Each uses its own occupation definition, survey basis and currency, so the numbers are not directly comparable with each other or with the US figures.
Canada (NOC 32120)
- Employment, 2020
- 20,180, Statistics Canada Census 2021 Official statistic Report an errorStatistics Canada Census of Population 2021: number of persons with employment income in NOC 32120 Medical laboratory technologists, Canada, reference year 2020. A recipients basis (anyone with employment income during the year), slightly broader than a point-in-time employed count. Statistics Canada Open Licence.
- Median pay, 2020
- C$79,500, Statistics Canada Census 2021 Official statistic Report an errorStatistics Canada Census of Population 2021 (Table 98-10-0586): median employment income for NOC 32120 Medical laboratory technologists, Canada, reference year 2020, full-year full-time workers (the basis comparable to the US OEWS full-time median). Statistics Canada Open Licence.
View all 17 years of cited US data, each linked to its source
| Year | US employment | Annual pay (median unless marked) | Source | Report |
|---|---|---|---|---|
| 1943 | 35,000 | n/a | Est., ASCLS Researched context | Report |
| 1986 | 239,350 | $22,000 | Est., Allied Health Services Researched context | Report |
| 2000 | 144,530 | $40,510 | BLS OEWS 2000 Official statistic | Report |
| 2003 | 146,900 | $43,640 | BLS OEWS May 2003 Official statistic | Report |
| 2004 | 151,240 | $45,730 | BLS OEWS May 2004 Official statistic | Report |
| 2005 | 155,250 | $47,710 | BLS OEWS May 2005 Official statistic | Report |
| 2006 | 160,760 | $49,700 | BLS OEWS May 2006 Official statistic | Report |
| 2007 | 163,270 | $51,720 | BLS OEWS May 2007 Official statistic | Report |
| 2008 | 166,510 | $53,500 | BLS OEWS May 2008 Official statistic | Report |
| 2009 | 166,860 | $55,140 | BLS OEWS May 2009 Official statistic | Report |
| 2010 | 164,430 | $56,130 | BLS OEWS May 2010 Official statistic | Report |
| 2011 | 165,220 | $57,010 | BLS OEWS May 2011 Official statistic | Report |
| 2012 | 160,700 | $57,580 | BLS OEWS May 2012 Official statistic | Report |
| 2013 | 162,630 | $58,430 | BLS OEWS May 2013 Official statistic | Report |
| 2014 | 161,710 | $59,430 | BLS OEWS May 2014 Official statistic | Report |
| 2015 | 162,950 | $60,520 | BLS OEWS May 2015 Official statistic | Report |
| 2016 | 166,730 | $61,070 | BLS OEWS May 2016 Official statistic | Report |